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Background: Though breast cancer is the most common cancer among women in Kerala, India, epidemiological
data on breast cancer in the state is largely lacking. The objectives of this study were to analyze the survival pattern
of female breast carcinoma in this region of the country and to compare the differences in survival with different
hormone-receptor expressions.
Methods: One hundred eighty-nine female breast cancer patients who were operated between 1 August 2008 and
3 July 2009 were followed up over telephone to obtain data on five-year survival. Grade, stage of the disease, and
hormone-receptor (HR) status were obtained from treatment records. Logistic regression and the Kaplan-Meier
survival analysis were used for statistical analysis.
Results: The mean age of the study population was 49.07 (SD, 10.35) years. A majority of the patients had estrogen
receptor (ER)+/progesterone receptor (PR) + tumors (n = 103, 54.5%), followed by 72 (38.1%) ER−/PR−, 10 (5.3%)
ER−/PR+, and 4 (2.1%) ER+/PR−. Stage of the disease, axillary nodal status, and hormone-receptor status showed
statistically significant association with overall survival in breast cancer. Overall survival rate at the end of 5 years
was 71.4%. Mortality was found to be highest for the ER − PR − group (47.2%).
Conclusions: Women in Kerala are diagnosed with breast carcinoma at a relatively younger age, yet the overall
five-year survival for the disease is low when compared to developed nations. It is imperative that comprehensive
breast cancer screening and treatment strategies be developed to enable earlier diagnosis and improve the survival
of breast cancer in the state.
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Breast cancer is the most common cancer among
women in many regions of India [1-3]. It is highly het-
erogeneous, with a wide range of biological, pathological,
and clinical characteristics [4]. Among these, hormone
receptors (estrogen receptor (ER), progesterone receptor
(PR)) greatly influence clinical outcome, and their role
as a prognostic and therapeutic tool is widely accepted* Correspondence: ajitvl@gmail.com
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unless otherwise stated.[5,6]. Though the incidence of breast cancer in Kerala
has been steadily mounting, data on epidemiology and
survival of breast cancer in the state is scarce.
The objectives of this study were to analyze the sur-
vival pattern of female breast carcinoma in this region of
the country and to compare the differences in survival
with different hormone-receptor expressions.Methods
A retrospective cohort study was conducted on 189 fe-
male patients who were diagnosed with invasive ductal
carcinoma and had undergone surgery between 1 AugustCentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 General characteristics of the study population




Grade I 13 6.8
II 104 55
III 72 38.1















ER + PR+ 103 54.5
ER + PR− 4 2.1
ER − PR+ 10 5.3
ER − PR− 72 38.1
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Surgery, Government Medical College, Thrissur. The
required information was collected from the treatment
records of the patients maintained at the Medical Records
Library. All data including age, menopausal status, and
pathological characteristics [grade (modified Bloom-
Richardson grade), stage of the disease (AJCC), tumor
size, and axillary nodal status] were recorded. Patients
whose hormone-receptor status was not analyzed were ex-
cluded from the study. Patients who had either ER or PR
positive tumors were treated with hormonal therapy.
Overall survival was calculated in months, either from the
date of diagnosis or from the date of surgery up to 31 De-
cember, 2013. Five-year survival at the end of the study
period was obtained from follow-up records for those who
were on regular follow-up and was confirmed by contact-
ing the patients or their relatives over telephone. Those
who had been lost to follow-up were also traced over
telephone.
All post-mastectomy specimens were evaluated for
hormone-receptor expression (ER and PR) by immuno-
histochemistry. In accordance with the American Society
of Clinical Oncology (ASCO) guidelines [7], which were
being followed when the assays were done, specimens in
which more than 10% of the tumor-nuclei stained posi-
tive were reported hormone-receptor positive. ER status
was determined using the BioGenex monoclonal mouse
IgG (Clone 1D5) (BioGenex, USA), and PR status was
determined using BioGenex monoclonal mouse IgG
(Clone 1A6) (BioGenex, USA). Antigen retrieval was
done using the BioGenex EZ-Retriever system (BioGenex,
USA). Based on hormone-receptor expression, patients
were grouped into four categories, that is, ER + PR+ (ER
positive PR positive), ER + PR−(ER positive PR negative),
ER − PR+ (ER negative PR positive), and ER − PR−(ER
negative PR negative).
Pathologic variables were compared using chi-square
test. Logistic regression analysis was carried out to assess
the independent association between different variables
and survival. The Kaplan-Meier method was used to es-
timate the overall survival.
Results
One hundred eighty-nine female patients with inva-
sive ductal breast cancer were included in the study.
The age of the patients ranged from 27 to 80 with a
median of 49.07 ± 10 years. ER expression was seen
in 107 patents (56.6%) and PR expression in 113 pa-
tients (59.8%).
General characteristics
The general characteristics of the study group are shown
in Table 1. Out of the 189 patients, 111 (58.7%) were
pre-menopausal. One hundred twenty-seven patients(67.2%) were between 41 and 60 years of age. Distribution
of patients according to their age and hormone-receptor
expression is shown in Table 2. A majority (n = 127,
67.2%) had stage 2 breast cancer at presentation. One
hundred four patients (55%) had grade 2 tumor, and 120
(63.2%) had tumor size between 2 and 5 cm.
Hormone-receptor expression and outcome
In this breast cancer cohort, 103 patients (54.5%) were
ER + PR+, 72 patients (38.1%) were ER − PR−, 10 patients
(5.3%) were ER − PR+, and 4 patients (2.1%) ER + PR−.
Mean follow-up time was 52 months. 71.4% of the pa-
tients (n = 135) were found to have survived to five years
from the time of diagnosis. Mortality was found to be
highest for the ER − PR − group (n = 38, 47.2%). Data re-
garding the four types of hormone-receptor expression
and the outcomes of patents that belonged to each group
is shown in Figure 1. Among the different age groups, pa-
tients aged 50 years or younger were found to have a higher
mortality (Table 2). The Kaplan-Meier survival curve was
Table 2 Distribution of patients according to their age and HR expression and their outcome
Age group Total ER + PR+ ER + PR− ER − PR+ ER − PR− Survival
N N (%) N (%) N (%) N (%) N (%)
21 to 30 5 1 (20) 0 0 4 (80) 1 (20)
31 to 40 36 23 (63.8) 1 (2.78) 3 (8.33) 9 (25) 27 (72.97)
41 to 50 79 46 (58.23) 0 2 (2.53) 31 (39.24) 59 (75.64)
51 to 60 48 20 (41.67) 3 (6.25) 5 (10.42) 20 (41.66) 35 (72.91)
61 to 70 16 10 (62.5) 0 0 6 (37.5) 11 (68.75)
71 to 80 5 3 (60) 0 0 2 (40) 2 (40)
Total 189 103 4 10 72
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pression and for overall survival (Figures 2 and 3).
Tables 3 and 4 show the association between different
variables and survival in breast cancer. Stage of the disease
(adjusted risk ratio (RR) 1.274), nodal status (adjusted RR
1.055), and hormone-receptor status (adjusted RR 2.859)
showed statistically significant association with overall
survival.
Discussion
Breast cancer is the most common cancer among urban
women and second most common among rural women
in India [1]. Breast cancer is a heterogeneous disease
that can be classified into several subtypes on the basis
of various clinical and pathological features [8]. Hormone-
receptor (ER and PR) status is now routinely determined
for all patients to assess the possibility of providing them
specific adjuvant hormone therapy [6].
The median age of the study group was 49.07 ±
10.35 years, which is very low compared to the USA,Figure 1 Pattern of hormone-receptor expression and survival.where the median age at diagnosis of breast cancer is
61 years [9-11]. This considerable difference can likely
be due to the genetic, racial, and socioeconomic differ-
ences between the two populations.
Data from the study showed that 56.6% patients were
ER+ and 54.5% patients were ER + PR+. This is low
when compared to data from the USA, where the overall
ER positivity is reported to be 77% [10]. The findings are
consistent with earlier studies from India [12-15]. We
also have a higher proportion of ER − PR − tumors com-
pared to the West. It has been noted that ER and PR ex-
pression in the study subjects increase with age. This is
in concordance with earlier studies [16,17]. A greater
number of ER − PR − tumors were seen in patients youn-
ger than 50 years of age.
Population-based studies on breast cancer in Banga-
lore [18] and Chennai [19] showed five-year survival
rates of 42.3% and 48%, respectively. The five-year sur-
vival rate of the current study cohort was much higher,
at 71.43%. The differences in the survival rate can be
Figure 2 Kaplan-Meier Curve for overall survival.
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has an average five-year survival rate of 89.2% for pa-
tients diagnosed with breast cancer [10]. The overall sur-
vival rate is still low compared to the West. Five-year
survival rates of more than 80% have been reported in
many studies from the West and also from a developed
Asian country [20,21]. Ethnicity and race have been doc-
umented as important factors that influence the survival
rate [22]. Along with these factors, well-established
screening programs and early detection of the disease
also help improve the survival rate.
ER + PR+ breast cancer has been independently associ-
ated with decreased breast cancer mortality in manyFigure 3 Kaplan-Meier Curve for survival for different hormone-receptor exstudies [4,19,23,24]. A similar survival pattern was also
noted in the current cohort, with highest mortality in the
ER − PR − group.
Stage of the disease, axillary nodal status, and hormone-
receptor status showed statistically significant association
with overall survival in breast cancer. Among these, the ax-
illary nodal status and stage of the disease are established
prognostic factors for carcinoma breast [5,16]. Along with
their proven role in determining therapeutic course, hor-
mone receptors (ER and PR) can also be used as a predict-
ive tool for breast cancer survival.
ER − PR+ is a rare subtype of breast cancer based on
hormone-receptor expression that accounts for 1% topression.
Table 3 Association of different variables to survival of
breast cancer (univariate analysis)










P value <0.05 significant.
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hort has a similar fraction of patients (5.3%) with ER −
PR+ expression, and 90% survival has been noted in this
particular group. The predictive value of PR in the ab-
sence of ER expression is controversial [26,27]. Some re-
ports suggest that positive PR in the absence of ER has a
higher response to hormone therapy, but this finding is
not universal [28-30]. Unfortunately, because of the rela-
tively small number of patients in the study group who
belonged to this subset, it is difficult to comment on the
role of this particular type of receptor expression on dis-
ease outcome.Conclusions
The overall five-year survival rate of breast cancer pa-
tients in Kerala is low compared to developed nations.
The lack of an effective cancer screening program is an
important reason for this. The higher proportion of
hormone-receptor (HR)-negative tumors in our popula-
tion may be due to delayed diagnosis along with other
genetic, ethnic, and cultural variations. Since data on
epidemiology and risk factors of the breast cancer in the
state is inadequate, it is very crucial to further explore
these aspects of the disease to develop a prevention and
control strategy to improve the survival rate.Table 4 Association of pathological variables and survival




95% CI for adjusted RR
Lower Upper
Tumor grade 1.451 0.73 2.884
Axillary nodal status 1.393 1.055 2.571
Stage of the disease 1.958 1.274 3.007
HR status 2.859 0.962 10.733
RR - risk ratio. Cox-Snell R2 0.271.Abbreviations
HR status: Hormone-receptor status; ER: Estrogen receptor; PR: Progesterone
receptor; RR: Risk ratio; ASCO: American Society of Clinical Oncology;
AJCC: American Joint Committee on Cancer.
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